ASHP’s Advocacy to Protect 340B Program Yields Important HRSA Ruling

In his latest blog post, ASHP Chief Executive Officer Paul W. Abramowitz discusses continued advocacy efforts to safeguard the 340B Drug Pricing Program and the recent actions taken by the Health Resources and Services Administration directing six drug manufacturers to comply with 340B pricing requirements or risk financial penalties.

Trusted Sources Critical for COVID-19 Vaccine Outreach